{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:14:47Z","timestamp":1790882087759,"version":"4.1.0"},"reference-count":54,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,5]]},"DOI":"10.1097\/bor.0b013e3282f5e08d","type":"journal-article","created":{"date-parts":[[2009,3,3]],"date-time":"2009-03-03T17:25:13Z","timestamp":1236101113000},"page":"263-268","source":"Crossref","is-referenced-by-count":80,"title":["New approaches of B-cell-directed therapy: beyond rituximab"],"prefix":"10.1097","volume":"20","author":[{"given":"Thomas","family":"D\u00f6rner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd R","family":"Burmester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-7-20210128","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/BOR.0b013e3280eec78c","article-title":"Emerging cytokine targets in rheumatoid arthritis","volume":"19","author":"Asquith","year":"2007","journal-title":"Curr Opin Rheumatol"},{"key":"R2-7-20210128","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/00002281-200305000-00011","article-title":"The role of B cells in rheumatoid arthritis: mechanisms and therapeutic targets","volume":"15","author":"D\u00f6rner","year":"2003","journal-title":"Curr Opin Rheumatol"},{"key":"R3-7-20210128","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/00002281-200405000-00013","article-title":"Rheumatoid factor revisited","volume":"16","author":"D\u00f6rner","year":"2004","journal-title":"Curr Opin Rheumatol"},{"key":"R4-7-20210128","first-page":"3","article-title":"Crossroads of B cell activation in autoimmunity: rationale of targeting B cells","volume":"33","author":"D\u00f6rner","year":"2006","journal-title":"J Rheumatol"},{"key":"R5-7-20210128","first-page":"1696","article-title":"Disease activity determines lymphoma risk in patients with rheumatoid arthritis. A nested case\u2013control study","volume":"40","author":"Baecklund","year":"1997","journal-title":"Arthritis Rheum"},{"key":"R6-7-20210128","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1002\/1529-0131(199908)42:8<1765::AID-ANR28>3.0.CO;2-V","article-title":"Malignant lymphoma in primary Sjogren's syndrome: a multicenter, retrospective, clinical study by the European concerted action on Sjogren's syndrome","volume":"42","author":"Voulgarelis","year":"1999","journal-title":"Arthritis Rheum"},{"key":"R7-7-20210128","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to antitumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R8-7-20210128","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/art.21778","article-title":"The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIb randomized, double-blind, placebo-controlled, dose-ranging trial","volume":"54","author":"Emery","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R9-7-20210128","doi-asserted-by":"crossref","first-page":"3580","DOI":"10.1002\/art.20592","article-title":"Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus","volume":"50","author":"Anolik","year":"2004","journal-title":"Arthritis Rheum"},{"key":"R10-7-20210128","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1002\/art.10541","article-title":"An open study of B lymphocyte depletion in systemic lupus erythematosus","volume":"46","author":"Leandro","year":"2002","journal-title":"Arthritis Rheum"},{"key":"R11-7-20210128","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1164\/rccm.200507-1144OC","article-title":"Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial","volume":"173","author":"Keogh","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"R12-7-20210128","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1002\/art.21260","article-title":"Rituximab treatment in patients with primary Sjogren's syndrome","volume":"52","author":"Pijpe","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R13-7-20210128","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nri1396","article-title":"Therapeutics targeting the innate immune system","volume":"4","author":"Ulevitch","year":"2004","journal-title":"Nat Rev Immunol"},{"key":"R14-7-20210128","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1172\/JCI107455","article-title":"Effects of corticosteroids on immunity in man 0.1. Decreased serum Igg concentration caused by 3 or 5 days of high doses of methylprednisolone","volume":"52","author":"Butler","year":"1973","journal-title":"J Clin Invest"},{"key":"R15-7-20210128","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1136\/ard.55.9.616","article-title":"Antibody deficiency associated with gold treatment: natural history and management in 22 patients","volume":"55","author":"Snowden","year":"1996","journal-title":"Ann Rheum Dis"},{"key":"R16-7-20210128","doi-asserted-by":"crossref","first-page":"489","DOI":"10.7326\/0003-4819-103-4-489","article-title":"Weekly pulse methotrexate in rheumatoid-arthritis: clinical and immunological effects in a randomized. Double-blind-study","volume":"103","author":"Andersen","year":"1985","journal-title":"Ann Inter Med"},{"key":"R17-7-20210128","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1093\/rheumatology\/kel366","article-title":"Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients","volume":"46","author":"Kapetanovic","year":"2007","journal-title":"Rheumatology"},{"key":"R18-7-20210128","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1517\/14712598.7.9.1287","article-title":"B-cell targeting: a novel approach to immune intervention today and tomorrow","volume":"7","author":"D\u00f6rner","year":"2007","journal-title":"Expert Opin Biol Ther"},{"key":"R19-7-20210128","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1385\/IR:28:1:61","article-title":"Monoclonal antibody therapy in experimental allergic encephalomyelitis and multiple sclerosis","volume":"28","author":"Zhang","year":"2003","journal-title":"Immunol Res"},{"key":"R20-7-20210128","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s00415-005-0934-5","article-title":"The window of therapeutic opportunity in multiple sclerosis","volume":"253","author":"Coles","year":"2006","journal-title":"J Neurol"},{"key":"R21-7-20210128","first-page":"S133","article-title":"Repeated B lymphocyte depletion therapy in rheumatoid arthritis: 5 year follow-up","volume":"52","author":"Edwards","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R22-7-20210128","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1093\/rheumatology\/kel393","article-title":"Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs","volume":"46","author":"Popa","year":"2007","journal-title":"Rheumatology"},{"key":"R23-7-20210128","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1002\/art.22019","article-title":"Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis","volume":"54","author":"Roll","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R24-7-20210128","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/rheumatology\/kel148","article-title":"Bone marrow B-lineage cells in patients with rheumatoid arthritis following rituximab therapy","volume":"46","author":"Leandro","year":"2007","journal-title":"Rheumatology"},{"key":"R25-7-20210128","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/art.22400","article-title":"Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis","volume":"56","author":"Vos","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R26-7-20210128","doi-asserted-by":"crossref","first-page":"R714","DOI":"10.1186\/ar1731","article-title":"Regeneration of the immunoglobulin heavy-chain repertoire after transient B-cell depletion with an anti-CD20 antibody","volume":"7","author":"Rouziere","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"R27-7-20210128","first-page":"S338","article-title":"Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis","volume":"52","author":"Leandro","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R28-7-20210128","first-page":"S66","article-title":"Safety and clinical activity of ocrelizumab (a humanized antibody targeting C D20+ B cells) in combination with methotrexate (M T X) in moderate\u2013severe rheumatoid arthritis (R A) patients (pts) (Ph I\/II ACTION study)","volume":"54","author":"Genovese","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R29-7-20210128","first-page":"C123","article-title":"Antilymphoma activity of a new humanized anti-CD20 monoclonal antibody, hA20","volume":"17","author":"Goldenberg","year":"2003","journal-title":"FASEB J"},{"key":"R30-7-20210128","first-page":"S67","article-title":"Serum B A FF levels correlate with B cell depletion in patients with rheumatoid arthritis treated with ocrelizumab","volume":"54","author":"Manning","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R31-7-20210128","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/rheumatology\/keh533","article-title":"Humanized anti-CD20 monoclonal antibody in the treatment of severe resistant systemic lupus erythematosus in a patient with antibodies against rituximab","volume":"44","author":"Tahir","year":"2005","journal-title":"Rheumatology"},{"issue":"Suppl 1","key":"R32-7-20210128","first-page":"SAT008","article-title":"Safety, pharmacodynamics, and clinical activity of ocrelizumab. A humanized anti-CD20 antibody in patients with moderate\u2013severe rheumatoid arthritis receiving methotrexate: a phase I\/II dose-ranging controlled trial","volume":"66","author":"Genovese","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"R33-7-20210128","first-page":"180","article-title":"TRU-015 improves rheumatoid arthritis disease activity in a randomized, double-blind, placebo-controlled, multicenter phase 2 dose ranging trial","volume":"65","author":"Burge","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R34-7-20210128","doi-asserted-by":"crossref","first-page":"R74","DOI":"10.1186\/ar1942","article-title":"Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus","volume":"8","author":"D\u00f6rner","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"R35-7-20210128","doi-asserted-by":"crossref","first-page":"R129","DOI":"10.1186\/ar2018","article-title":"Epratuzumab (humanised anti-CD22 antibody) in primary Sjogren's syndrome: an open-label phase I\/II study","volume":"8","author":"Steinfeld","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"R37-7-20210128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-2776(05)88001-0","article-title":"CD22: a multifunctional receptor that regulates B lymphocyte survival and signal transduction","volume":"88","author":"Tedder","year":"2005","journal-title":"Adv Immunol"},{"key":"R38-7-20210128","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1172\/JCI0214121","article-title":"Association of BAFF\/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome","volume":"109","author":"Groom","year":"2002","journal-title":"J Clin Invest"},{"key":"R39-7-20210128","first-page":"12","article-title":"Updates from B cell trials: efficacy","volume":"33","author":"Cohen","year":"2006","journal-title":"J Rheumatol"},{"key":"R40-7-20210128","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1365-2141.2006.06431.x","article-title":"High-level serum B-cell activating factor and promoter polymorphisms in patients with idiopathic thrombocytopenic purpura","volume":"136","author":"Emmerich","year":"2007","journal-title":"Br J Haematol"},{"key":"R41-7-20210128","first-page":"S1432","article-title":"Safety, pharmacokinetics, and pharmacodynamic of multiple doses of BR3-Fc in adults with rheumatoid arthritis","volume":"56","author":"Shaw","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R42-7-20210128","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/35010115","article-title":"TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease","volume":"404","author":"Gross","year":"2000","journal-title":"Nature"},{"key":"R43-7-20210128","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S1074-7613(01)00183-2","article-title":"TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease: impaired B cell maturation in mice lacking BLyS","volume":"15","author":"Gross","year":"2001","journal-title":"Immunity"},{"key":"R44-7-20210128","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/nri1886","article-title":"Competence and competition: the challenge of becoming a long-lived plasma cell","volume":"6","author":"Radbruch","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"R45-7-20210128","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/ncprheum0142","article-title":"T-cell-targeted therapies in rheumatoid arthritis","volume":"2","author":"Weyand","year":"2006","journal-title":"Nat Clin Pract Rheumatol"},{"key":"R46-7-20210128","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1191\/0961203305lu2136oa","article-title":"Block and tackle: CTLA4Ig takes on lupus","volume":"14","author":"Davidson","year":"2005","journal-title":"Lupus"},{"key":"R47-7-20210128","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/art.10856","article-title":"A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis","volume":"48","author":"Boumpas","year":"2003","journal-title":"Arthritis Rheum"},{"key":"R48-7-20210128","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1002\/art.10681","article-title":"Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial","volume":"46","author":"Kalunian","year":"2002","journal-title":"Arthritis Rheum"},{"key":"R49-7-20210128","first-page":"S227","article-title":"Remission of proliferative lupus nephritis following anti-B cell therapy is preceded by downregulation of the T cell costimulatory molecule CD40-ligand","volume":"50","author":"Sfikakis","year":"2004","journal-title":"Arthritis Rheum"},{"key":"R50-7-20210128","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev.immunol.22.012703.104533","article-title":"CD40\/CD154 interactions at the interface of tolerance and immunity","volume":"22","author":"Quezada","year":"2004","journal-title":"Annu Rev Immunol"},{"key":"R51-7-20210128","first-page":"S947","article-title":"Preliminary safety and efficacy of baminercept (LT\u03b2R-Ig, BG9924) in the treatment of rheumatoid arthritis","volume":"56","author":"Baldassare","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R52-7-20210128","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.immuni.2007.09.002","article-title":"Antibodies and B cell memory in viral immunity","volume":"27","author":"D\u00f6rner","year":"2007","journal-title":"Immunity"},{"key":"R53-7-20210128","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/nm917","article-title":"Duration of antiviral immunity after smallpox vaccination","volume":"9","author":"Hammarlund","year":"2003","journal-title":"Nat Med"},{"key":"R54-7-20210128","first-page":"86","article-title":"Serious infection rates in patients receiving biologic therapy in the United Kingdom: results from the BSR biologics register (BSRBR)","volume":"64","author":"Dixon","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"R55-7-20210128","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1002\/art.21386","article-title":"Infections in patients with rheumatoid arthritis treated with biologic agents","volume":"52","author":"Listing","year":"2005","journal-title":"Arthritis Rheum"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/BOR.0b013e3282f5e08d","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:54:05Z","timestamp":1786038845000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002281-200805000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0b013e3282f5e08d","relation":{},"ISSN":["1040-8711"],"issn-type":[{"value":"1040-8711","type":"print"}],"subject":[],"published":{"date-parts":[[2008,5]]}}}